Complete Guide to Datopotamab Deruxtecan (Datroway) Pharmacokinetics
Overview
Datopotamab Deruxtecan (Datroway) is a Antibody-Drug Conjugate (ADC) used in the Oncology therapeutic area. It is indicated for Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload. Population PK simulator for datopotamab deruxtecan (Dato-DXd, Datroway) — TROP2-directed ADC for NSCLC and breast cancer. Simulates intact ADC (2-CMT, parallel linear + Michaelis-Menten clearance) and free DXd payload with albumin and body weight covariates. Based on Hong et al. CPT:PSP 2025. Compare payload exposure to T-DXd.
Mechanism of Action
Datopotamab Deruxtecan (Datroway) exerts its pharmacological effect by targeting TROP2. As a Antibody-Drug Conjugate (ADC), it modulates this target to achieve therapeutic efficacy in Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This Population PK (2-CMT ADC parallel linear+MM + 1-CMT Payload) model for Datopotamab Deruxtecan (Datroway) characterizes the time-course of drug concentrations following IV Infusion administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
Datopotamab Deruxtecan (Datroway) is administered via the IV Infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology therapeutic area, for the treatment of Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload, understanding the pharmacokinetics of Datopotamab Deruxtecan (Datroway) is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Datopotamab Deruxtecan (Datroway) pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive Datopotamab Deruxtecan (Datroway) PK Simulator
Explore Datopotamab Deruxtecan (Datroway) pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Datopotamab Deruxtecan (Datroway)?
The elimination half-life of Datopotamab Deruxtecan (Datroway) depends on patient-specific factors. Use our interactive Datopotamab Deruxtecan (Datroway) PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Datopotamab Deruxtecan (Datroway) administered?
Datopotamab Deruxtecan (Datroway) is administered via the IV Infusion route. It is indicated for Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload. As a Antibody-Drug Conjugate (ADC), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Datopotamab Deruxtecan (Datroway)?
Key pharmacokinetic parameters for Datopotamab Deruxtecan (Datroway) include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a Population PK (2-CMT ADC parallel linear+MM + 1-CMT Payload) model to characterize the pharmacokinetics of Datopotamab Deruxtecan (Datroway).
Can I simulate Datopotamab Deruxtecan (Datroway) dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Datopotamab Deruxtecan (Datroway) PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.